FDA Greenlights Oculis' Privosegtor Pathway for Acute MS Relapses
Event summary
- FDA confirms Privosegtor data can be cross-referenced for new IND application in acute MS relapses.
- IND submission planned for Q4 2026, leveraging existing Phase 2 ACUITY study results.
- Privosegtor targets neuroaxonal damage during relapses, addressing unmet need in RRMS treatment.
- Oculis to host R&D Day in Q4 2026 to detail Privosegtor's development strategy.
The big picture
Oculis is positioning Privosegtor as a first-in-class neuroprotective therapy for acute MS relapses, expanding beyond its core focus on optic neuritis. The FDA's support validates the company's strategy to leverage existing data for new indications, potentially reducing development costs and time. With 85% of MS patients initially diagnosed with relapsing-remitting MS (RRMS), Privosegtor could address a significant unmet need in a $2.8 million global patient population.
What we're watching
- Regulatory Pathway
- Whether the FDA's constructive feedback will accelerate Privosegtor's approval timeline for acute MS relapses.
- Clinical Strategy
- How Oculis will integrate optic neuritis data into the acute MS relapse development plan.
- Market Opportunity
- The pace at which Privosegtor can capture share in the $170,000 annual U.S. MS relapse market.
Related topics